The big-pharma firm that saw the future
Long ago Roche bet on personalised health care. Now its time has come
ROCHE IS A strange entity. The Swiss giant is the world’s second-biggest drugmaker and one of big pharma’s most profitable firms. But its largest shareholding group, mostly descended from Fritz Hoffmann-La Roche, who founded the company in 1896, is led by André Hoffmann, a nature lover and sustainability advocate who believes that the purpose of business is not mainly to make money. Even its bosses are discouraged from making a quick franc. Severin Schwan, an Austrian who has led the company since 2008, is only Roche’s seventh CEO in 125 years. Much of his pay is tied up in company stock for ten years, giving him, as he puts it, “literally a vested interest” in its long-term future.
This article appeared in the Business section of the print edition under the headline “The firm that saw the future”
More from Business
Donald Trump’s America will not become a tech oligarchy
Reasons not to panic about the tech-industrial complex
OpenAI’s latest model will change the economics of software
The more reasoning it does, the more computer power it uses
TikTok’s time is up. Can Donald Trump save it?
The imperilled app hopes for help from an old foe
The UFC, Dana White and the rise of bloodsport entertainment
There is more to the mixed-martial-arts impresario than his friendship with Donald Trump
Will Elon Musk scrap his plan to invest in a gigafactory in Mexico?
Donald Trump’s return to the White House may have changed Tesla’s plans
Germany is going nuts for Dubai chocolate
Will the hype last?